Navigation Links
Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
Date:12/17/2008

l be presented at an upcoming medical meeting, along with additional efficacy data from the 240 mg/day and lower dose groups. Final selection of the Phase 3 dose will be made following completion of data analyses.

"We are pleased to have reached another development milestone in our prostate cancer program by successfully completing enrollment in our Phase 1-2 clinical trial in castration-resistant prostate cancer patients with limited treatment options," said Lynn Seely, M.D., chief medical officer of Medivation. "We look forward to presenting additional data from this trial and to advancing this program into Phase 3 development in 2009, as we have previously guided."

About Prostate Cancer and MDV3100

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer. An estimated 186,320 new cases are expected to be diagnosed in 2008, and approximately 28,660 men are expected to die this year from the disease. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Overexpression of the androgen receptor is believed to contribute to the progression of castration-resistant prostate cancer. MDV3100 is a novel small-molecule androgen receptor antagonist that inhibits androgen receptor function by blocking nuclear translocation of the androgen receptor and DNA binding.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation entered into a global agreement with Pfizer Inc to de
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
7. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
8. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
9. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
10. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
11. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Minn. , Aug. 1, 2014 ... medical technologies company, announced today that it has ... held manufacturer of cardiorespiratory diagnostic products based in ... MediSoft has served the European cardiorespiratory diagnostics market ... 2013 revenues of approximately €4.7 million ($6.3 million) ...
(Date:8/1/2014)... 1, 2014 Dyadic International, Inc. ("Dyadic") (OTCQX: ... technologies are used to develop, manufacture and sell enzymes ... and industrial enzyme industries, announced today that it will ... June 30, 2014 after market close on Thursday, August ... day at 5:00 p.m. Eastern Time to discuss those ...
(Date:7/31/2014)... 2014  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ; ... , Chief Business Officer and Executive Vice President. Mr. Singh ... 30. "Sorrento is deeply saddened and shocked by ... thoughts go to Amar,s family and friends," said Henry ... Mr. Singh joined Sorrento in January 2014 from ...
Breaking Medicine Technology:MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 4Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3Sorrento Announces the Unexpected Death of its Chief Business Officer 2
... Oct. 8 Breast-Specific Gamma Imaging (BSGI), a molecular ... resonance imaging (MRI) for detecting breast carcinoma when used ... and is substantially less expensive than MRI, according to ... Oncology Breast Cancer Symposium in San Francisco, California. , ...
... Calif., Oct. 8 Endologix, Inc. (Nasdaq: ELGX ), ... that it has become aware that Cook Medical has filed ... alleging that Endologix infringes two of Cook,s U.S. patents. , ... have just become aware of the lawsuit filed by Cook ...
Cached Medicine Technology:Breast-Specific Gamma Imaging Proves Cost-Effective for Pre-Surgical Planning of Patients with Known Cancer Diagnosis 2Endologix Comments on Alleged Patent Infringement 2
(Date:8/1/2014)... 2014 St. Christopher's Hospital for Children ... episode of Innovations with Ed Begley Jr, airing later ... times TBA. , St. Christopher's Hospital for Children offers ... from birth through 21 years of age. With over ... hospital's specialties, including autism and childhood obesity. , ...
(Date:8/1/2014)... August 01, 2014 Narconon Arrowhead recently ... program at the drug rehab center located in the ... 2001, Narconon Arrowhead is the flagship drug rehab center ... the United States for services there. Now, with such ... recent outcome studies as well as client reviews showing ...
(Date:8/1/2014)... Arlington, TX (PRWEB) August 01, 2014 ... of the Year for its outstanding commitment to St. ... for the hospital since 1999 and pledging to raise ... to combat childhood cancer and other deadly diseases. ... from any single partner in St. Jude history. Specifically, ...
(Date:8/1/2014)... HealthDay Reporter THURSDAY, July 31, 2014 ... of heart attack and stroke, particularly if you work in ... officials reported Thursday. But being unemployed might be just ... include job stress, exposure to air pollution -- like dust ... Sara Luckhaupt, from the National Institute for Occupational Safety and ...
(Date:8/1/2014)... 01, 2014 For the first time, ... Cotton Farm & Fiber Report and the Organic Cotton ... entire organic cotton supply chain resulting in the ... organization’s Managing Director, reports, “We are looking holistically at ... the beginning of a long value chain and surveying ...
Breaking Medicine News(10 mins):Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 3Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 2Health News:Narconon Arrowhead Celebrates 4,300th Graduate from Program 3Health News:St. Jude Children’s Research Hospital® Names Tri Delta Fraternity Partner of the Year 2Health News:St. Jude Children’s Research Hospital® Names Tri Delta Fraternity Partner of the Year 3Health News:Some Jobs Harder on the Heart Than Others, Report Finds 2Health News:Surveys Reveal the Top 10 Organic Cotton Users and the Top 10 Producing Countries 2
... ... shows vacations with animals will help the family bond. Spending quality time with the family often ... ... families are finding it exciting and different to spend their vacations at a Dude or Guest ...
... ... Legal Hold Pro™ service into doeDiscovery™. Further expanding doeLegal,s capabilities across the entire spectrum ... to offer increased value to all eDiscovery clients. , ... (PRWEB) May 14, 2010 -- doeLegal, ...
... essays look at ethical issues arising from new neuroimaging ... severe brain injury might be able to communicate. ... Authors: J. Andrew Billings, Larry R. Churchill, and Richard ... or a meaningful existence? The authors contend that ...
... ... luminaries in science , ... New York, NY (Vocus) May 13, 2010 -- Mount Sinai School of Medicine ... field of genetics and human genome research, and renowned humanists whose work has advanced ...
... Recognizing ... by cancer, CIGNA expands access to all Cancer Treatment Centers of America physicians and facilities. ... Chicago, IL (PRWEB) May ... customers who have been touched by cancer, CIGNA has entered into a new agreement that ...
... affects 1 in 20 people over age 65, experts ... By treating the common irregular heartbeat known as atrial ... prevent Alzheimer,s disease and other forms of dementia, new ... of the heart beat chaotically, causing blood to pool ...
Cached Medicine News:Health News:Independent Study Reveals Family Bonds made Stronger on Vacations where Animals are Involved 2Health News:Independent Study Reveals Family Bonds made Stronger on Vacations where Animals are Involved 3Health News:Independent Study Reveals Family Bonds made Stronger on Vacations where Animals are Involved 4Health News:doeLegal and Zapproved Sign Alliance to Add Legal Hold Pro to Suite of Powerful Online Legal Solutions 2Health News:doeLegal and Zapproved Sign Alliance to Add Legal Hold Pro to Suite of Powerful Online Legal Solutions 3Health News:The Hastings Center Report table of contents for May/June 2010 2Health News:The Hastings Center Report table of contents for May/June 2010 3Health News:Mount Sinai School of Medicine Commencement Honors Leaders in Genetics and Global Health 2Health News:Mount Sinai School of Medicine Commencement Honors Leaders in Genetics and Global Health 3Health News:Mount Sinai School of Medicine Commencement Honors Leaders in Genetics and Global Health 4Health News:Mount Sinai School of Medicine Commencement Honors Leaders in Genetics and Global Health 5Health News:Mount Sinai School of Medicine Commencement Honors Leaders in Genetics and Global Health 6Health News:CIGNA and Cancer Treatment Centers of America Reach New Agreement 2Health News:Treating Common Irregular Heartbeat Might Also Ward Off Alzheimer's 2Health News:Treating Common Irregular Heartbeat Might Also Ward Off Alzheimer's 3
The Reusable Purse String Clamp is intended for use in the mechanical construction of a purse string suture. The clamp can be used on any part of the gastrointestinal tract except the esophagus....
... VALTRAC™ Single Use Biofragmentable Anastomosis ... end-to-end, end-to-side and side-to-side anastomosis., ... and multiple intestinal anastomoses but not ... device may be used in any ...
The Auto Suture™ EEA™ 34mm reusable stainless steel sizer has application in intestinal, colorectal and esophageal surgery to help evaluate the diameter of tubular structures....
... in the parafollicular C-cells of the thyroid ... The major action of calcitonin is to ... activity, resulting in decreased mobilization of calcium ... evident in conditions associated with high levels ...
Medicine Products: